Climb Bio CEO trades shares under 10b5-1 plan

Climb Bio, Inc. President and CEO Aoife Brennan exercised restricted stock units and sold shares in a planned transaction.

Rhea-AI Filing Summary

Climb Bio, Inc. President and CEO Aoife Brennan exercised restricted stock units and sold shares in a planned transaction. On June 27, 2026, 68,750 RSUs converted into the same number of common shares as part of a four-year vesting grant. On June 29, 2026, Brennan sold 30,902 common shares at a weighted average price of $13.17 per share pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations tied to the RSU vesting. After these transactions, Brennan directly owned 87,731 common shares, including 1,751 acquired through the employee stock purchase plan, and continued to hold RSUs scheduled to vest annually over four years.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Brennan Aoife

Role President and CEO

Sold 30,902 shs ($407K)

Approx. gross sale proceeds $407K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	30,902	$13.17	$407K
Exercise	Restricted Stock Units	68,750	$0.00	$0.00
Exercise	Common Stock	68,750	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 137,500 contracts (Direct); Common Stock — 87,731 shares (Direct)

Footnotes (6)

1. F1. Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock
2. F2. Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
3. F3. The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
5. F5. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
6. F6. The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

Key Figures

Shares sold: 30,902 shares Weighted average sale price: $13.17 per share RSUs converted: 68,750 units +3 more

6 metrics

Shares sold 30,902 shares Open-market sale on June 29, 2026

Weighted average sale price $13.17 per share Common stock sale range $13.02–$13.34

RSUs converted 68,750 units RSUs converted into common stock on June 27, 2026

Shares owned after transactions 87,731 shares Direct common stock holdings following June 29, 2026 sale

RSUs outstanding after conversion 137,500 RSUs Restricted stock unit balance after June 27, 2026 transaction

ESPP shares included 1,751 shares Employee Stock Purchase Plan shares within total holdings

Key Terms

Restricted Stock Units, Rule 10b5-1 trading plan, Employee Stock Purchase Plan, weighted average price, +1 more

5 terms

Restricted Stock Units financial

"The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Purchase Plan financial

"Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vesting financial

"are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Climb Bio (CLYM) report for Aoife Brennan?

Climb Bio reported that President and CEO Aoife Brennan exercised 68,750 restricted stock units into common shares, then sold 30,902 shares in an open-market transaction under a Rule 10b5-1 trading plan to address tax withholding obligations from the RSU vesting.

How many Climb Bio (CLYM) shares did the CEO sell and at what price?

Aoife Brennan sold 30,902 shares of Climb Bio common stock at a weighted average price of $13.17 per share, with individual trade prices ranging between $13.02 and $13.34, as disclosed in the Form 4 footnote describing the transaction price range.

Were the Climb Bio (CLYM) CEO’s share sales pre-planned under Rule 10b5-1?

Yes. The Form 4 states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 30, 2024, specifically to cover tax withholding obligations arising from the vesting and settlement of Aoife Brennan’s restricted stock units.

How many Climb Bio (CLYM) shares does the CEO hold after these transactions?

Following the reported exercise and sale, Aoife Brennan directly owned 87,731 shares of Climb Bio common stock. This total includes 1,751 shares acquired through the company’s Employee Stock Purchase Plan, as detailed in a Form 4 footnote on post-transaction holdings.

What are the vesting terms of the Climb Bio (CLYM) CEO’s restricted stock units?

The restricted stock units were granted on June 27, 2024 and are scheduled to vest over four years. Twenty-five percent of the RSUs vest on each of the first four anniversaries of the grant date, conditioned on Aoife Brennan’s continued service with the company.

How many restricted stock units did the Climb Bio (CLYM) CEO convert?

Aoife Brennan converted 68,750 restricted stock units into an equal number of Climb Bio common shares. Each RSU represents a contingent right to receive one share, and the conversion reflects vesting under a previously granted equity award with multi-year vesting terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 07:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Aoife

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MASSACHUSETTS 02481

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/27/2026		M		68,750	A	(1)	118,633(2)	D
Common Stock	06/29/2026		S(3)		30,902	D	$13.17(4)	87,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(5)	06/27/2026		M			68,750	(6)	(6)	Common Stock	68,750	$0.00	137,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock

2. Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.

3. The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

5. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

6. The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

	/s/ Chandra Adams, as Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)